Acute Liver Failure Including Acetaminophen Overdose

Medical Clinics of North America

Volumn 92, Issue 4, 2008, Pages 761-794

  Fontana, Robert J ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ACTIVATED CARBON; ALANINE AMINOTRANSFERASE; BILIRUBIN; IPECAC; ISONIAZID; PARACETAMOL; PHENYTOIN;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DRUG BLOOD LEVEL; DRUG OVERDOSE; EMERGENCY SURGERY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; INTERNATIONAL NORMALIZED RATIO; JAUNDICE; LIVER FAILURE; LIVER TOXICITY; LIVER TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROGNOSIS; PROTHROMBIN TIME; REVIEW; RISK FACTOR; STOMACH LAVAGE; SURVIVAL RATE; TOXICOLOGY; TREATMENT OUTCOME; URINALYSIS;

ACETAMINOPHEN; ANALGESICS, NON-NARCOTIC; HUMANS; LIVER FAILURE, ACUTE; LIVER TRANSPLANTATION; OVERDOSE; PROGNOSIS;

EID: 44949233782     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2008.03.005     Document Type: Review

References (136)

1. Trey C., and Davidson C.S. The management of fulminant hepatic failure. In: Popper H., and Schaffner F. (Eds). Progress in Liver Disease (1970), Grune & Stratton, New York 282-298
2. Polson J.P., and Lee W.M. American Association for the Study of Liver Disease position paper: the management of acute liver failure. Hepatology 41 (2005) 1179-1197
3. Ostapowicz G.A., Fontana R.J., Schiodt F.V., et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 137 (2002) 947-954
4. Hoofnagle J.H., Carithers R.L., Shapiro C., et al. Fulminant hepatic failure: summary of a workshop. Hepatology 21 (1995) 240-253
5. Squires R.H., Shneider B.L., Bucuvalas J., et al. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group. J Pediatr 148 (2006) 652-658
6. Larson A.M., Polson J., Fontana R.J., et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology 42 (2005) 1364-1372
7. Taylor R.M., Davern T., Munoz S., et al. Fulminant hepatitis A virus in the United States: incidence, prognosis, and outcomes. Hepatology 44 (2006) 1589-1597
8. Lisman T., Leebeek F.W.G., and DeGroot P.G. Haemostatic abnormalities in patients with liver disease. J Hepatol 37 (2002) 280-287
9. Ring-Larsen H., and Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut 22 (1981) 585-591
10. Vaquero J., Polson J., Chung C., et al. Infection and the progression of encephalopathy in acute liver failure. Gastroenterology 125 (2003) 755-764
11. Nourjah P., Ahmad S.R., Karwoski C., et al. Estimates of acetaminophen (Paracetamol)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf 15 (2006) 398-405
12. Fontana R.J., and Adams P.C. "Unintentional" acetaminophen overdose on the rise: who is responsible?. Can J Gastroenterol 20 (2006) 319-324
13. Smilkstein M.J., Knapp G.L., Kulig K.W., et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976-1985). N Engl J Med 319 (1988) 1557-1562
14. Zimmerman H.J., and Maddrey W.C. Acetaminophen hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology 22 (1995) 767-773
15. Kuffner E.K., Dart R.C., Bogdan G.M., et al. Effect of maximal daily doses of acetaminophen on the liver of alcoholic patients: a randomized, double-blind, placebo-controlled trial. Arch Intern Med 161 (2001) 2247-2252
16. Nolan C.M., Sandblom R.E., Thummel K.E., et al. Hepatotoxicity associated with acetaminophen usage in patients receiving multiple drug therapy for tuberculosis. Chest 105 (1994) 408-411
17. Whitcomb D.C., and Block G.D. Association of acetaminophen hepatotoxicity with fasting and alcohol use. JAMA 272 (1994) 1845-1850
18. Watkins P.B., Kaplowitz N., Slattery J.T., et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily. JAMA 296 (2006) 87-93
19. Schiodt F.V., Rochling F.A., Casey D.L., et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med 337 (1997) 1112-1117
20. Rumack B.H. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol 40 (2002) 3-20
21. Polson J., Orsulak P.J., Wians F., et al. Elevated bilirubin may cause false positive acetaminophen levels in hepatitis patients. [abstract]. Hepatology 40 (2004) 496A
22. James L.P., Mayeux P.R., and Hinson J.A. Acetaminophen-induced hepatotoxicity. Drug Metab Dispos 31 (2003) 1499-1506
23. Davern T.J., James L.P., Hinson J., et al. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 130 (2006) 687-694
24. Sato R.L., Wong J.J., Sumida S.M., et al. Efficacy of superactivated charcoal administration late (3 hours) after acetaminophen overdose. Am J Emerg Med 21 (2003) 189-191
25. Kao L.W., Kirk M.A., Furbee R.B., et al. What is the rate of adverse events after oral N-acetylcysteine administered by the intravenous route to patients with suspected acetaminophen poisoning?. Ann Emerg Med 42 (2003) 741-750
26. Kaplowitz N. Acetaminophen hepatotoxicity: what do we know, what we don't know, and what do we do next?. Hepatology 40 (2004) 24-26
27. Hawton K., Townsend E., Deeks J., et al. Effects of legislation restricting pack sizes of paracetamol and salicylate on self poisoning in the United Kingdom: before and after study. BMJ 322 (2001) 1-7
28. Hawton K., Simkin S., Deeks J., et al. UK legislation in analgesic packs: before and after study of long term effect on poisonings. BMJ 329 (2004) 1076-1079
29. Food and Drug Administration, 21 CRF Parts 201 and 343. Internal analgesic, antipyretic, and antirheumatic drug products for over the counter human use: proposed amendment of the tentative final monograph, required warnings and other labeling. Federal Register 71 247 (2006) 77314-77352
30. Rezende G., Roque-Afonso A.M., Samuel D., et al. Viral and clinical factors associated with the fulminant course of hepatitis A infection. Hepatology 38 (2003) 613-618
31. Recommended adult immunization schedule-United States October 2006-September 2007. MMWR 55 (2006) 2430-2433
32. Wai C.T., Fontana R.J., Polson J., et al. Clinical outcome and virological characteristics of hepatitis B related acute liver failure in the United States. J Viral Hepat 12 (2005) 192-198
33. Teo E.K., Ostapowicz G., Hussain M., et al. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 33 (2001) 972-976
34. Schmilovitz-Weiss H., Ben-Ari Z., Sikular E., et al. Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int 24 (2004) 547-551
35. Kumar M., Satapathy S., Monga R., et al. A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 45 (2007) 97-101
36. Seremba E., Sanders C., Jain M., et al. Use of nucleoside analogues in HBV related acute liver failure. [abstract]. Hepatology 46 Suppl 1 (2007) 79
37. Kharoo M.S., and Kamili S. Aetiology and prognostic factors in acute liver failure in India. J Viral Hepat 10 (2003) 224-231
38. Pal R., Aggarwal R., Naik S.R., et al. Immunological alterations in pregnant women with acute hepatitis E. J Gastroenterol Hepatol 20 (2005) 1094-1101
39. Shrestha M.P., McNair Scott R., Joshi D.M., et al. Safety and efficacy of recombinant hepatitis E vaccine. N Engl J Med 356 (2007) 895-903
40. Kang A.H., and Graves C.R. Herpes simplex hepatitis in pregnancy: a case report and review of the literature. Obstet Gynecol Surv 54 (1999) 463-468
41. Peters D.J., Greene W.H., Ruggiero F., et al. Herpes simplex induced fulminant hepatitis in adults: a call for empiric therapy. Dig Dis Sci 45 (2000) 2399-2404
42. Dits H., Frans E., Wilmer A., et al. Varicella-zoster virus infection associated with acute liver failure. Clin Infect Dis 27 (1998) 209-210
43. Levitsky J., Thadareddy A., Lakeman F.D., et al. Measurement of herpes simplex DNA-emia before and after liver transplantation. Liver Transpl (2008) in press
44. Ichai P., Alfonso A.M., Sebagh M., et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 11 (2005) 1550-1555
45. Lee W.M., and Senior J.R. Recognizing drug induced liver injury: current problems, possible solutions. Toxicol Pathol 33 (2005) 155-164
46. Sgro C., Clinard F., Ouazir L., et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 36 (2002) 451-455
47. Watkins P.B., and Seeff L.B. Drug induced liver injury: summary of a single topic clinical research conference. Hepatology 43 (2006) 618-631
48. Bjornsson E., and Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 42 (2005) 481-489
49. Andrade R.J., Lucena M.I., Fernandez M.C., et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 129 (2005) 512-521
50. Verma A., and Lilienfeld D.E. The need for a population-based surveillance system for liver disease in the United States. Pharmacoepidemiol Drug Saf 13 (2004) 821-824
51. Lee W.M. Drug-induced hepatotoxicity. N Engl J Med 349 (2003) 474-485
52. Hoofnagle J.H. Drug induced liver injury network (DILIN). Hepatology 40 (2004) 773
53. Aithal P.G., and Day C.P. The natural history of histologically proved drug induced liver disease. Gut 44 (1999) 731-735
54. Dechene A., Treichel U., Gerken G., et al. Effectiveness of a steroid and ursodeoxycholic acid combination therapy with drug induced subacute liver failure. [abstract]. Hepatology 42 (2005) 358A
55. Rakela J., Mosley J.W., Edwards V.M., et al. A double-blinded randomized trial of hydrocortisone in acute hepatic failure. Dig Dis Sci 36 (1991) 1223-1228
56. Danan G., and Benichou C. Causality assessment of adverse reactions-a novel method based on conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 46 (1993) 1323-1330
57. Lucena M.I., Camargo R., Andrade R.J., et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology 33 (2001) 123-130
58. Favreau J.T., Fyu M.L., Braunstein G., et al. Severe hepatotoxicity associated with the dietary supplement LipoKinetix. Ann Intern Med 136 (2002) 590-595
59. Estes J.D., Stolpman D., Olyaei A., et al. High prevalence of potentially hepatotoxic herbal supplement use in patients with fulminant hepatic failure. Arch Surg 138 (2003) 852-858
60. Watt K., Molinari M., Kruszyna T., et al. Acute liver failure induced by green tea extracts: case report and review of the literature. Liver Transpl 12 (2006) 1892-1895
61. Shapiro M.A., and Lewis J.H. Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. Clin Liver Dis 11 (2007) 477-505
62. Ohmori S., Shiraki K., Inoue H., et al. Clinical characteristics and prognostic indicators of drug induced fulminant hepatic failure. Hepatogastroenterology 50 (2003) 1531-1534
63. Russo M.W., Galanko J.A., Shrestha R., et al. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 10 (2004) 1018-1023
64. Kessler W.R., Cummings O.Q., Eckert G., et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol 2 (2004) 625-631
65. Rolfes D.B., and Ishak K.G. Acute fatty liver of pregnancy: a clinicopathologic study of 35 cases. Hepatology 5 (1985) 1149-1158
66. Weinstein L. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol 142 (1982) 159-167
67. Pereira S.P., O'Donohue J., Wendon J., et al. Maternal and perinatal outcome in severe pregnancy-related liver disease. Hepatology 26 (1997) 1258-1262
68. Ibdah J.A., Bennett M.J., Rinaldo P., et al. A fetal fatty-acid oxidation disorder as a cause of liver disease in pregnant women. N Engl J Med 340 (1999) 1723-1731
69. Fickert P., Ramschak H., Kenner L., et al. Acute Budd-Chiari syndrome with fulminant hepatic failure in a pregnant woman with factor V Leiden mutation. Gastroenterology 111 (1996) 1670-1673
70. Olzinski A.T., and Sanyal A.J. Treating Budd-Chiari syndrome: making rational choices from a myriad of options. J Clin Gastroenterol 30 (2000) 155-161
71. Taylor R.M., Fontana R.J., Shakil A.O., et al. Acute liver failure due to ischemic hepatitis: natural history and predictors of outcome in a prospective, multi-center U.S. study. [abstract]. Gastroenterology 128 4 Supp 2 (2005) A-706
72. Broussard C.N., Aggarwal A., Lacey S.R., et al. Mushroom poisoning-from diarrhea to liver transplantation. Am J Gastroenterol 96 (2001) 3195-3198
73. Klein A.S., Hart J., Brems J.J., et al. Amanita poisoning: treatment and the role of liver transplantation. Am J Med 86 (1989) 187-193
74. Roberts E.A., and Schilsky M.L. American Association for the Study of Liver Disease practice guidelines: a practice guideline on Wilson disease. Hepatology 37 (2003) 1475-1492
75. Nazer H., Ede R.J., Mowat A.P., et al. Wilson's disease: clinical presentation and use of prognostic index. Gut 27 (1986) 1377-1381
76. Woolf G.M., Petrovic L.M., Rojter S.E., et al. Acute liver failure due to lymphoma. A diagnostic concern when considering liver transplantation. Dig Dis Sci 391 (1994) 1351-1358
77. Shehab T.M., Kaminski M.S., and Lok A.S.F. Case report: acute liver failure due to hepatic involvement by hematologic malignancy. Dig Dis Sci 42 7 (1997) 1400-1405
78. Wigg A.J., Gunson B.K., and Mutimer D.J. Outcomes following liver transplantation for seronegative acute liver failure: experience during a 12-year period with more than 100 patients. Liver Transpl 11 (2005) 27-34
79. Lee W.M., Brown K.E., Young N.S., et al. Brief report: no evidence of parvovirus B19 or hepatitis E virus as causes of acute liver failure. Dig Dis Sci 51 (2006) 1712-1715
80. Umemura T., Tanaka E., Ostapowicz G., et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis 188 (2003) 1545-1552
81. Ware A.J., Jones R.E., Shorey J.W., et al. A controlled trial of steroid therapy in massive hepatic necrosis. Am J Gastroenterol 62 (1974) 130-133
82. Sterling R.K., Luketic V.A., Sanyal A.J., et al. Treatment of fulminant hepatic failure with intravenous prostaglandin E1. Liver Transpl Surg 4 (1998) 424-431
83. Harrison P.M., Wendon J.A., Gimson E.S., et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med 324 (1991) 1852-1857
84. Sklar G.E., and Subramaniam M. Acetylcysteine treatment for non-acetaminophen-induced acute liver failure. Ann Pharmacother 38 (2004) 498-501
85. Lee W.M., Rossaro L., Fontana R.J., et al. Intravenous N-acetylcysteine improves spontaneous survival in early stage non-acetaminophen acute liver failure. [abstract]. Hepatology 46 Suppl 1 (2007) 79
86. Wijdicks E.F.M., Plevak D.J., Rakela J., et al. Clinical and radiologic features of cerebral edema in fulminant hepatic failure. Mayo Clin Proc 70 (1995) 119-124
87. Itai Y., Sekiyama K., Ahmadi T., et al. Fulminant hepatic failure: observation with serial CT. Radiology 202 (1997) 379-382
88. Jalan R. Pathophysiological basis of therapy of raised intracranial pressure in acute liver failure. Neurochem Int 47 (2005) 78-83
89. Clemmesen J.O., Larsen F.S., Kondrup J., et al. Cerebral herniation in patients with acute liver failure is correlated with arterial ammonia concentration. Hepatology 29 (1999) 648-653
90. Larsen F.S., Ejlersen E., Hansen B.A., et al. Functional loss of cerebral blood flow autoregulation in patients with fulminant hepatic failure. J Hepatol 23 (1995) 212-217
91. Vaquero J., Fontana R.J., Larson A.M., et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl 11 (2005) 1581-1589
92. Durward Q.J., Amacher A.L., Del Maestro R.F., et al. Cerebral and cardiovascular responses to changes in head elevation in patients with intracranial hypertension. J Neurosurg 59 (1983) 938-944
93. Yano M., Nishiyama H., Yokota H., et al. Effect of lidocaine on ICP response to endotracheal suctioning. Anesthesiology 64 (1986) 651-653
94. Strauss G., Hansen B.A., Knudsen G.M., et al. Hyperventilation restores cerebral blood flow autoregulation in patients with acute liver failure. J Hepatol 28 (1998) 199-203
95. Canalese J., Gimson A.E., Davis C., et al. Controlled trial of dexamethasone and mannitol for the cerebral oedema of fulminant hepatic failure. Gut 23 (1982) 625-629
96. Murphy N., Auzinger G., Bernal W., et al. The effect of hypertonic sodium chloride on intracranial pressure in patients with acute liver failure. Hepatology 39 (2004) 464-470
97. Forbes A., Alexander G.J., O'Grady J.G., et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology 10 (1989) 306-310
98. Wijkicks E.F.M., and Nyberg S.L. Propofol to control intracranial pressure in fulminant hepatic failure. Transplant Proc 34 (2002) 1220-1222
99. Jalan R., Olde Damink S.W., Deutz N.E., et al. Restoration of cerebral blood flow autoregulation and reactivity to carbon dioxide in acute liver failure by moderate hypothermia. Hepatology 34 (2001) 50-54
100. Jalan R., Damink S.W., Deutz N.E., et al. Moderate hypothermia prevents cerebral hyperemia and increase in intracranial pressure in patients undergoing liver transplantation for acute liver failure. Transplantation 75 (2003) 2034-2039
101. Jalan R., Olde Damink S.W., Deutz N.E., et al. Moderate hypothermia in patients with acute liver failure and uncontrolled intracranial hypertension. Gastroenterology 127 (2004) 1338-1346
102. Ellis A.J., Wendon J.A., and Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology 32 (2000) 536-541
103. Wade J., Rolando N., Philpott-Howard J., et al. Timing and etiology of bacterial infections in a liver intensive care unit. J Hosp Infect 53 (2003) 144-146
104. Cobden I., Record C.O., Ward M.K., et al. Paracetamol-induced acute renal failure in the absence of fulminant liver damage. Br Med J 284 (1982) 21-22
105. Bernal W., Donaldson N., Wyncoll D., et al. Blood lactate as an early predictor of outcome in paracetamol-induced acute liver failure: a cohort study. Lancet 359 (2002) 558-563
106. Davenport A., Will E.J., and Davidson A.M. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med 21 (1993) 328-338
107. Shawcross D.L., Davies N.A., Mookerjee R.P., et al. Worsening of cerebral hyperemia by the administration of terlipressin in acute liver failure with severe encephalopathy. Hepatology 39 (2004) 471-475
108. Drews R., and Weinberger S. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med 162 (2000) 347-351
109. Cook D., Guyatt G., Marshall J., et al. A comparison of sucralfate and ranitidine for the prevention of upper gastrointestinal bleeding in patients requiring mechanical ventilation. N Engl J Med 338 (1998) l791-l797
110. Shami V.M., Caldwell S.H., Hespenheide E.E., et al. Recombinant activated factor VII for coagulopathy in fulminant hepatic failure compared with conventional therapy. Liver Transpl 9 (2003) 138-143
111. Caldwell S.H., Chang C., and Macik B.G. Recombinant activated factor VII as a hemostatic agent in liver disease: a break from convention in need of controlled trials. Hepatology 39 (2004) 592-598
112. Ritt D.J., Whelan G., Werner D.J., et al. Acute hepatic necrosis with stupor or coma. An analysis of 31 patients. Medicine 48 (1969) 151-172
113. Schiodt F.V., Atillasoy E., Shakil A.O., et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg 5 (1999) 29-34
114. Higgins P.D., and Fontana R.J. Liver transplantation in acute liver failure. Panminerva Med 52 (2002) 93-97
115. McDiarmid S.V., Goodrich N.P., Harper A.M., et al. Liver transplantation for status 1: the consequences of good intentions. Liver Transpl 13 (2007) 699-707
116. Neuberger J. Prediction of survival for patients with fulminant hepatic failure. Hepatology 41 (2005) 19-21
117. O'Grady J. Attempting to predict the unpredictable in acute liver injury. J Hepatol 42 (2005) 5-6
118. O'Grady J.G., Alexander G.J., Hayllar K.M., et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology 97 (1989) 439-455
119. Anand A.C., Nightingale P., and Neuberger J.M. Early indicators of prognosis in fulminant hepatic failure: an assessment of the King's criteria. J Hepatol 26 (1997) 62-68
120. Pauwels A., Mostefa-Kara N., Florent C., et al. Emergency liver transplantation for acute liver failure: evaluation of London and Clichy criteria. J Hepatol 17 (1993) 124-127
121. Weisner R., Edwards E., Freeman R., et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 124 (2003) 91-96
122. Kremers W.K., Ijperen M.V., Kim W.R., et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 39 (2004) 764-769
123. Mitchell I., Bihari D., Chang R., et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med 26 (1998) 279-284
124. Schmidt L.E., and Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology 36 (2002) 659-665
125. Schiodt F.V., Ostapowicz G., Murray N., et al. Alpha-fetoprotein and prognosis in acute liver failure. Liver Transpl 12 (2006) 1776-1781
126. Schmidt L.E., and Dalhoff K. Alpha-fetoprotein is a predictor of outcome in acetaminophen-induced liver injury. Hepatology 41 (2005) 26-31
127. Shakil A.O., Jones B.C., Lee R.G., et al. Prognostic value of abdominal CT scanning and hepatic histopathology in patients with acute liver failure. Dig Dis Sci 45 (2000) 334-339
128. Hanau C., Munoz S.J., and Rubin R. Histopathological heterogeneity in fulminant hepatic failure. Hepatology 21 (1995) 345-351
129. Wiesner R.H. MELD/PELD and the allocation of deceased donor livers for status 1 recipients with acute fulminant hepatic failure, primary nonfunction, hepatic artery thrombosis, and acute Wilson's disease. Liver Transpl 10 (2004) S17-S22
130. 2006 organ procurement and transplantation network/scientific registry of transplant recipients annual report, Table 9.2a. Available at:. http://www.optn.org/AR2006902a_lihtm Accessed September 25, 2007
131. O'Grady J.G., Gimson A.E., O'Brien C.J., et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 94 (1988) 1186-1192
132. Redeker A.G., and Yamahiro H.S. Controlled trial of exchange-transfusion therapy in fulminant hepatitis. Lancet 1 (1973) 3-6
133. Sen S., and Williams R. New liver support devices in acute liver failure: a critical evaluation. Semin Liver Dis 23 (2003) 283-294
134. Rifai K., Ernst T., Kretschmer U., et al. The Prometheus device for extracorporeal support of combined liver and renal failure. Blood Purif 23 (2005) 298-302
135. Demetriou A.A. Hepatic assist devices. Panminerva Med 47 (2005) 31-37
136. Demetriou A.A., Brown Jr. R.S., Busuttil R.W., et al. Prospective, randomized, multicenter controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 239 (2004) 660-667